Tezspire™ (tezepelumab-ekko) – New drug approval
On December 17, 2021, Amgen and AstraZeneca announced the FDA approval of Tezspire (tezepelumab-ekko), for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Download PDF
